Literature DB >> 30395729

Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis.

Shashank Gupta1,2, Stefanie Krug1, Supriya Pokkali1,3, Tomas Leanderson4, John T Isaacs1, Geetha Srikrishna1, William R Bishai1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30395729      PMCID： PMC6363972          DOI： 10.1164/rccm.201805-0820LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  10 in total

1.  Bacterial subversion of cAMP signalling inhibits cathelicidin expression, which is required for innate resistance to Mycobacterium tuberculosis.

Authors:  Shashank Gupta; Kathryn Winglee; Richard Gallo; William R Bishai
Journal:  J Pathol       Date:  2017-03-15       Impact factor: 7.996

2.  Neutrophils and the S100A9 protein critically regulate granuloma formation.

Authors:  Yuya Yoshioka; Tatsuaki Mizutani; Satoshi Mizuta; Ayumi Miyamoto; Satoru Murata; Toshiaki Ano; Hiroshi Ichise; Daisuke Morita; Hiroyuki Yamada; Yoshihiko Hoshino; Tatsuaki Tsuruyama; Masahiko Sugita
Journal:  Blood Adv       Date:  2016-12-14

3.  Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis.

Authors:  Julia K Knaul; Sabine Jörg; Dagmar Oberbeck-Mueller; Ellen Heinemann; Lisa Scheuermann; Volker Brinkmann; Hans-Joachim Mollenkopf; Vladimir Yeremeev; Stefan H E Kaufmann; Anca Dorhoi
Journal:  Am J Respir Crit Care Med       Date:  2014-11-01       Impact factor: 21.405

4.  Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.

Authors:  Li Shen; Anette Sundstedt; Michael Ciesielski; Kiersten Marie Miles; Mona Celander; Remi Adelaiye; Ashley Orillion; Eric Ciamporcero; Swathi Ramakrishnan; Leigh Ellis; Robert Fenstermaker; Scott I Abrams; Helena Eriksson; Tomas Leanderson; Anders Olsson; Roberto Pili
Journal:  Cancer Immunol Res       Date:  2014-11-04       Impact factor: 11.151

5.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.

Authors:  Bo Huang; Ping-Ying Pan; Qingsheng Li; Alice I Sato; David E Levy; Jonathan Bromberg; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.

Authors:  John T Isaacs; Roberto Pili; David Z Qian; Susan L Dalrymple; Jason B Garrison; Natasha Kyprianou; Anders Björk; Anders Olsson; Tomas Leanderson
Journal:  Prostate       Date:  2006-12-01       Impact factor: 4.104

7.  Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.

Authors:  Shashank Gupta; Laurene Cheung; Supriya Pokkali; Kathryn Winglee; Haidan Guo; John R Murphy; William R Bishai
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

Review 8.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

9.  Concordant and discordant gene expression patterns in mouse strains identify best-fit animal model for human tuberculosis.

Authors:  Teresa Domaszewska; Lisa Scheuermann; Karin Hahnke; Hans Mollenkopf; Anca Dorhoi; Stefan H E Kaufmann; January Weiner
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

Review 10.  Mechanisms of action of tasquinimod on the tumour microenvironment.

Authors:  E Raymond; A Dalgleish; J-E Damber; M Smith; R Pili
Journal:  Cancer Chemother Pharmacol       Date:  2013-10-27       Impact factor: 3.333
  10 in total
  5 in total

Review 1.  Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.

Authors:  Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

2.  Effective Host-Directed Therapy for Tuberculosis by Depletion of Myeloid-Derived Suppressor Cells and Related Cells Using a Diphtheria Toxin Fusion Protein.

Authors:  Sadiya Parveen; Shichun Lun; Michael E Urbanowski; Mitchell Cardin; Jessica Shen; John R Murphy; William R Bishai
Journal:  J Infect Dis       Date:  2021-12-01       Impact factor: 5.226

Review 3.  The Emerging Role of Myeloid-Derived Suppressor Cells in Tuberculosis.

Authors:  Tandeka Magcwebeba; Anca Dorhoi; Nelita du Plessis
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

Review 4.  Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis.

Authors:  Stefanie Krug; Sadiya Parveen; William R Bishai
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 7.561

5.  Immunosuppressive Features of the Microenvironment in Lymph Nodes Granulomas from Tuberculosis and HIV-Co-Infected Patients.

Authors:  Senait Ashenafi; Jagadeeswara Rao Muvva; Akhirunnesa Mily; Johanna Snäll; Martha Zewdie; Menberework Chanyalew; Anders Rehn; Sayma Rahman; Getachew Aseffa; Amsalu Bekele; Getachew Aderaye; Beede Lema; Mattias Svensson; Susanna Brighenti
Journal:  Am J Pathol       Date:  2022-01-31       Impact factor: 5.770
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.